Lung cell therapy shows promise in IPF trial
Disease control
Completed
This study tested a new cell therapy called REGEND001 for people with idiopathic pulmonary fibrosis (IPF), a serious lung disease. The therapy uses special lung cells to try to repair damaged tissue. In this phase 2 trial, 23 participants received either the cell therapy or a pla…
Phase: PHASE2 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC